Jakafi is a registered trademark of Incyte Corporation.
©
2011-2013,
Incyte Corporation. All rights reserved.
RUX-1057e 04/13
Jakafi is indicated for treatment of patients with intermediate or high-risk MF,
including primary MF, post–PV MF and post–ET MF.
For US Residents Only | Non-US Residents
IncyteCARES
A comprehensive program created by Incyte to connect both physicians and myelofibrosis patients to access, reimbursement, education and support for Jakafi® (ruxolitinib).
Jakafi® (ruxolitinib) for intermediate or high-risk myelofibrosis
Jakafi® (ruxolitinib) is an oral JAK1 and JAK2 inhibitor treatment indicated for patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post–polycythemia vera myelofibrosis and post–essential thrombocythemia myelofibrosis—collectively known as myelofibrosis diseases.1 Learn more about myelofibrosis treatment with Jakafi® (ruxolitinib).
COMFORT-I = COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment (I).
Reference:
- Jakafi Prescribing Information. Incyte Corporation. June 2012.
